Mucosal antibody responses following Vaxzevria vaccination

• DOI: 10.1111/imcb.12685
• Publication Date: 2023-09-06T01:50:57Z
• Authors: Kevin J Selva; Pradhipa Ramanathan; Ebene R Haycroft; Chee Wah Tan; Lin‐Fa Wang; Laura E Downie; Samantha K Davis; Ruth A Purcell; Helen E Kent; Jennifer A Juno; Adam K Wheatley; Miles P Davenport; Stephen J Kent; Amy W Chung
• Keywords: Immunoglobulin A

Abstract Mucosal antibodies play a key role in protection against breakthrough COVID‐19 infections and emerging viral variants. Intramuscular adenovirus‐based vaccination (Vaxzevria) only weakly induces nasal IgG IgA responses, unless vaccinees have been previously infected. However, little is known about how Vaxzevria impacts the ability of mucosal to induce Fc particularly SARS‐CoV‐2 variants concern (VoCs). Here, we profiled paired (saliva, tears) plasma from vaccinated (uninfected, vaccinated) recovered (COVID‐19 recovered, who both received vaccines. ancestral‐specific capable engaging FcγR3a were significantly higher samples comparison with vaccinees. when tested panel VoCs, responses ancestral‐centric weaker recognition Omicron strains observed. In contrast, salivary IgA, but not displayed broad cross‐reactivity across all VoCs tested. Our data highlight that while intramuscular can enhance vaccinees, restrictions by bias may implications for protection. highly cross‐reactive could be addressing these gaps immunity an important focus future vaccine development.